Skip to main content
FDA Approval

FDA Grants Accelerated Approval to Neladalkib for Previously Treated Patients With ALK-Positive Non-Small Cell Lung Cancer

Edited by 

Clinical Summary: 

  • Regulatory Update: The FDA has granted accelerated approval to neladalkib for patients with ALK-positive locally advanced or metastatic non-small cell lung cancer previously treated with either alectinib as their single prior ALK tyrosine kinase inhibitor or at least 2 prior ALK tyrosine kinase inhibitors and platinum-based chemotherapy. 
  • Key Outcomes: This approval was based on results from the ALKOVE-1 trial, in which neladalkib demonstrated an objective response rate of 49% among patients previously treated with alectinib and 32% among those who received at least 2 ALK tyrosine kinase inhibitors and platinum-based chemotherapy. Approximately half of responders in both populations maintained responses for at least 12 months. 
  • Clinical Relevance: This approval introduces an additional oral targeted treatment option for patients with previously treated ALK-positive advanced non-small cell lung cancer, including those who have progressed following multiple prior systemic therapies. 

On November 17, 2026, the US Food and Drug Administration (FDA) granted accelerated approval to neladalkib (Nelkarmi; Nuvalent) for patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) previously treated with alectinib as their single prior ALK tyrosine kinase inhibitor (TKI) or at least 2 prior ALK TKIs and platinum-based chemotherapy, introducing an additional oral targeted treatment option in this setting.  

This approval was based on results from the multicenter, single-arm, open-label ALKOVE-1 trial, which evaluated neladalkib in two patient populations: patients who had received 1 prior ALK TKI consisting of alectinib (n = 67) and patients who had received at least 2 prior ALK TKIs and platinum-based chemotherapy (n = 155). 

Primary end points included confirmed overall response rate (ORR) and duration of response, assessed by blinded independent central review according to RECIST version 1.1. A key secondary end point was safety. 

Among patients previously treated with alectinib, the ORR was 49%. Among responding patients, 76% maintained their response for at least 6 months, and 52% maintained their response for at least 12 months. 

Among patients previously treated with at least 2 ALK TKIs and platinum-based chemotherapy, the ORR was 32%. In this heavily pretreated population, 69% of responding patients maintained their response for at least 6 months, and 51% maintained their response for at least 12 months.

The most common adverse reactions, occurring in at least 20% of patients, included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue.

The recommended dose of neladalkib is 150 mg orally once daily, with or without food, taken at the same time each day until disease progression or unacceptable toxicity.

The prescribing information includes warnings and precautions for hepatotoxicity, renal toxicity, ocular toxicity, creatine phosphokinase elevation, and embryo-fetal toxicity. 

The FDA accelerated approval expands targeted treatment options for patients with previously treated ALK-positive advanced NSCLC, including those who have received multiple prior ALK inhibitors and platinum-based chemotherapy, while further evaluation of clinical benefit remains important.


Source:

US Food and Drug Administration. FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer. Accessed on: November 17, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-neladalkib-previously-treated-locally-advanced-or-metastatic-alk

© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of LL&M, Oncology Learning Network or HMP Global, their employees, and affiliates.